Venkatesh Chelvam, Shen Jiayin, Putt Karson S, Low Philip S
Discipline of Chemistry, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.
Discipline of Bioscience and Biomedical Engineering, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.
Cancer Drug Resist. 2021 Mar 19;4(1):223-232. doi: 10.20517/cdr.2020.84. eCollection 2021.
: Ligand-targeted therapeutics are experiencing increasing use for treatment of human diseases due to their ability to concentrate a desired drug at a pathologic site while reducing accumulation in healthy tissues. For many ligand-targeted drug conjugates, a critical aspect of conjugate design lies in engineering release of the therapeutic payload to occur only after its internalization by targeted cells. Because disulfide bond reduction is frequently exploited to ensure intracellular drug release, an understanding of the redox properties of endocytic compartments can be critical to ligand-targeted drug design. While the redox properties of folate receptor trafficking endosomes have been previously reported, little is known about the trafficking of prostate-specific membrane antigen (PSMA), a receptor that is experiencing increasing use for drug targeting in humans. : To obtain this information, we have constructed a PSMA-targeted fluorescence resonance energy transfer pair that reports on disulfide bond reduction by changing fluorescence from red to green. : We show here that this reporter exhibits rapid and selective uptake by PSMA-positive cells, and that reduction of its disulfide bond proceeds steadily but incompletely following internalization. The fact that maximal disulfide reduction reaches only ~50%, even after 24 h incubation, suggests that roughly half of the conjugates must traffic through endosomes that display no reducing capacity. : As the level of disulfide reduction differs between PSMA trafficked and previously published folate trafficked conjugates, it also follows that not all internalizing receptors are translocated through similar intracellular compartments. Taken together, these data suggest that the efficiency of disulfide bond reduction must be independently analyzed for each receptor trafficking pathway when disulfide bond reduction is exploited for intracellular drug release.
由于能够将所需药物集中在病理部位,同时减少在健康组织中的积累,配体靶向疗法在人类疾病治疗中的应用越来越广泛。对于许多配体靶向药物偶联物而言,偶联物设计的一个关键方面在于设计治疗性有效载荷的释放,使其仅在被靶向细胞内化后才发生。由于二硫键还原常被用于确保细胞内药物释放,因此了解内吞小室的氧化还原特性对于配体靶向药物设计至关重要。虽然先前已报道了叶酸受体转运内体的氧化还原特性,但对于前列腺特异性膜抗原(PSMA)的转运了解甚少,PSMA是一种在人类药物靶向中应用越来越广泛的受体。
为了获得这些信息,我们构建了一个PSMA靶向的荧光共振能量转移对,通过将荧光从红色变为绿色来报告二硫键的还原情况。
我们在此表明,该报告分子在PSMA阳性细胞中表现出快速且选择性的摄取,并且其二硫键在内化后稳定但不完全地进行还原。即使在孵育24小时后,最大二硫键还原仅达到约50%,这一事实表明大约一半的偶联物必须通过没有还原能力的内体进行转运。
由于PSMA转运的偶联物与先前发表的叶酸转运的偶联物之间二硫键还原水平不同,因此也可以得出结论,并非所有内化受体都通过相似的细胞内区室进行转运。综上所述,这些数据表明,当利用二硫键还原进行细胞内药物释放时,必须针对每个受体转运途径独立分析二硫键还原的效率。
Cancer Drug Resist. 2021-3-19
Proc Natl Acad Sci U S A. 2006-9-12
Proc Natl Acad Sci U S A. 2005-12-13
Mol Ther Nucleic Acids. 2024-4-23
Cancer Drug Resist. 2021
Chem Rev. 2017-9-12
Wien Med Wochenschr. 2016-5